Log In
Print
BCIQ
Print
Print this Print this
 

Resolor, prucalopride (SHP555) (formerly SPD 555)

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionSerotonin (5-HT4) receptor agonist
Molecular Target Serotonin (5-HT4) receptor
Mechanism of ActionSerotonin (5-HT4) receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationConstipation
Indication DetailsTreat chronic constipation (CC); Treat non-cancer related opioid-induced constipation (OIC)
Regulatory Designation
Partner Johnson & Johnson

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$559.5M

$559.5M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today